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Abstract There are currently about 80 different DNA
tests available for mutations that are associated with
inherited disease in the domestic dog, and as the tools
available with which to dissect the canine genome become
increasingly sophisticated, this number can be expected to
rise dramatically over the next few years. With unrelenting
media pressure focused ﬁrmly on the health of the purebred
domestic dog, veterinarians and dog breeders are turning
increasingly to DNA tests to ensure the health of their dogs.
It is ultimately the responsibility of the scientists who
identify disease-associated genetic variants to make sensi-
ble choices about which discoveries are appropriate to
develop into commercially available DNA tests for the lay
dog breeder, who needs to balance the need to improve the
genetic health of their breed with the need to maintain
genetic diversity. This review discusses some of the factors
that should be considered along the route from mutation
discovery to DNA test and some representative examples
of DNA tests currently available.
Introduction
In December 2004 the $30 million project funded by the
National Human Genome Research Institute (NHGRI) in
the United States to sequence the entire dog genome was
completed and the results made publicly available. The
NHGRI made the decision to fund such an expensive
undertaking because it recognised the dog as an unrivalled
model organism with which to study the genetics of a wide
range of inherited traits, including inherited disease,
behaviour, and morphology. Although the NHGRI’s
motives for sequencing all the DNA in the dog were pri-
marily human-centric, the ﬁndings that have emerged
from the canine genome project, and that will continue to
materialise for many years to come, have profound impli-
cations for both veterinary and human medical research.
Most importantly, the pace at which genetic variants
associated with inherited canine diseases have been iden-
tiﬁed has increased dramatically and will continue to do so
as the tools available to dissect the genetic basis of canine
inherited traits become increasingly more sophisticated.
Studies over the last decade, aimed at understanding the
genetic basis of inherited traits in the domestic dog, have
revealed mutations in dozens of genes, some of them novel,
which are now worthy candidates for further study in other
species, including man. In addition to mutations associated
with Mendelian traits, an ever-increasing number of loci
that are associated with genetically complex conditions are
being reported. Many of these will almost certainly shed
light on the development of similar conditions in other
species as well.
A better understanding of the nature and function of
some of the genes identiﬁed in the dog that are associated
with equivalent conditions in man will no doubt lead, in the
long term, to improved diagnosis and treatment for human
patients. It is also possible that many of these downstream
beneﬁts will eventually also be applicable to dogs. But by
far the most likely and immediate improvement to the
health of domestic dogs will derive from the DNA tests that
are routinely made available once a disease-associated
mutation has been identiﬁed. Currently, DNA tests are
available for over 80 different canine mutations, a number
that can be expected to increase very quickly in the coming
years, and over 120 breeds are able to take advantage of at
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at the time of writing is given in Table 1, although it should
be noted that new DNA tests are becoming available very
rapidly so readers should check with individual testing
laboratories for a complete list of tests available. Alterna-
tive resources for ﬁnding lists of currently available DNA
tests are http://www.thekennelclub.org.uk/item/2108, http://
www.offa.org/dna_alltest.html, and http://www.akcchf.org/
canine-health/genetic-tests/. This article does not attempt to
discuss every test available. Rather it discusses some of the
considerations that should be taken into account to suc-
cessfully translate scientiﬁc ﬁndings into robust and useful
tools for the lay dog breeder to use, and in so doing it uses a
few representative examples of DNA tests that are currently
available.
The domestic dog, inherited disease, and DNA testing
Intense selection, high levels of inbreeding, the extensive
use of a limited number of sires, and genetic isolation are
all hallmarks of modern breeds of domestic dog. It is
widely agreed that part of the collateral damage from these
practices is that purebred dogs have a greater risk of suf-
fering from genetically simple inherited disorders than
their cross-breed cousins. Intense media interest continues
to apply pressure on both dog breeders and the veterinary
profession to improve the health of purebred dogs, the
result being that these stakeholders are turning increasingly
to DNA tests to assist with both breeding decisions and
also the diagnostic process. Some dog breeders are
exceptionally well informed when it comes to genetics and
possess a very good understanding of the inherited disor-
ders that affect their breed(s). But many are not, and they
rely on their general practice veterinarian for information,
who also may not have a good knowledge of the majority
of inherited conditions that affect all the different breeds
they encounter.
It is, therefore, ultimately the responsibility of the sci-
entists who identify genetic variants associated with canine
inherited disorders to exercise prudence when they make
DNA tests available. Purebred dog populations, by deﬁni-
tion, are genetically compromised, with many having an
unequivocal need to maximise diversity. Breeders are
increasingly using DNA tests to shape their breeding
decisions, with the need to reduce the frequency of dele-
terious mutations being balanced with the need to maintain
genetic diversity. There is a critical need, therefore, for full
and transparent information, written in lay terms, explain-
ing (1) the mode of inheritance and penetrance of speciﬁc
mutations, (2) the risk of disease associated with speciﬁc
genotypes, (3) the frequency of each mutation within dif-
ferent breed populations, and (4) the breeds that are
genuinely at risk, so that dogs are not unnecessarily elim-
inated from the breeding population. The existence of
phenocopies within the breed, if known, should also be
documented.
DNA testing of companion animals is unregulated, and
so one of the few ways in which potential ‘‘customers’’ can
judge the merit of any DNA test is if a description of the
mutation on which the test is based has been accepted by a
peer-reviewed scientiﬁc publication. However, the data
that establish a genetic variant as a provocative candidate
for downstream, comparative studies (and therefore worthy
of publication) is not always the same information that a
dog owner needs to discern whether they should use the
DNA test and what decisions to make in light of the results.
It is therefore not sufﬁcient for a DNA test provider merely
to provide a hyperlink to a peer-reviewed publication
without backing it up with some layman-friendly
explanation.
It is worth noting that once a mutation has been reported
in the scientiﬁc literature there is little stopping private,
for-proﬁt organisations from offering a genetic test based
on a published ﬁnding, irrespective of the opinion of the
scientists who made the discovery. Therefore, suggesting
that researchers have absolute control over which DNA
tests are offered might be an oversimpliﬁcation in some
cases. Nevertheless, scientists should certainly be encour-
aged to offer ‘‘user-friendly’’ advice on how to use genetic
tests and to work with dog breed clubs and organisations to
disseminate this advice. Perhaps they should also be will-
ing to suggest when consideration of a particular disease-
associated variant to shape breeding decisions is
inappropriate.
DNA tests for recessive mutations
The vast majority of DNA tests currently available are for
autosomal recessive mutations associated with Mendelian
or single-gene traits. Some of these traits are morphologi-
cal, such as coat colour, but most are for disease mutations,
many of which are severe and debilitating. Providing
advice to breeders for these tests is generally very
straightforward; essentially all dogs can be safely bred,
regardless of their genotype, provided both the sire and the
dam have been tested and carriers and genetically affected
dogs are mated only to dogs that are clear of the mutation.
Often, the initial reaction of breeders is to avoid breeding
with all but homozygous wild-type (?/?) dogs, and indeed
many members of the veterinary community who were
indoctrinated to never breed affected dogs condone this
view. However, if a mutation is frequent within a breed,
breeders should be counselled to include carriers in the
breeding population, for at least a generation, to avoid
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Breed Condition / coat colour Company or testing laboratory
Afghan Hound Canine Coat and Nose Colour HealthGene
Canine Mask Test HealthGene
Airedale Terrier Haemophilia B HealthGene, Cornell University
Factor V11 Deﬁciency VetGen, Laboklin
Alaskan Malamute Coat Length VDA, AHT
Cone Degeneration Optigen
American Eskimo Dog Progressive Retinal Atrophy, prcd Optigen
American Pit Bull Terrier Cone rod dystrophy 2 (crd2)Cerebellar Ataxia
(NCL-A)
Optigen
American Staffordshire Terrier Cerebellar Ataxia (NCL-A) Optigen
Australian Cattle Dog Progressive Retinal Atrophy, prcd OptiGen, Genetic Technologies Ltd, Laboklin
Coat Colour Variations VetGen
Australian Shepherd Cone Degeneration (CD) Optigen
Canine Multi-focal Retinopathy Optigen
Collie Eye Anomaly (CEA) / choroidal
hypoplasia (CH)
Optigen, Genetic Technologies Ltd
Hereditary Cataract (HC-HSF4) AHT, Genoscoper
Multi drug resistance (MDR1) HealthGene, Genetic Technologies Ltd,
Laboklin, Finnzymes
Progressive Retinal Atrophy, prcd OptiGen, Genetic Technologies Ltd, Laboklin
Cobalamin Malabsorption (Methylmalonic
Aciduria)
PennGen
Canine Coat and Nose Colour HealthGene
Bobtail gene AHT, Genoscoper
Australian Terrier von Willebrand’s disease Genetic Technologies Ltd
Basenji Pyruvate Kinase (PK) Deﬁciency OptiGen, HealthGene, VetGen, PennGen,
Laboklin, Genetic Technologies Ltd,
Genindexe, van Haeringen
* Fanconi Syndrome University of Missouri
Basset Hound X-linked severe combined immunodeﬁciency
(SCID)
PennGen, Laboklin, Genetic Technologies
Ltd
Thrombopathia Auburn University
Beagle Pyruvate Kinase Deﬁciency PennGen, genetic technologies Ltd; Laboklin
Coagulation Factor VII deﬁciency AHT, PennGen, VetGen, Laboklin
Musladin-Lueke Syndrome University of California
Bedlington Terrier Copper Toxicosis* VetGen, HealthGene, AHT, VetGen, van
Haeringen, VDA, Finnzymes, Laboklin,
Genetic Technologies Ltd
Copper Toxicosis, COMMD1 AHT, VetGen, Genetic Technologies Ltd
Belgian Shepherd Canine Coat and Nose Colour HealthGene
- Groenendael Canine Coat and Nose Colour HealthGene
- Laekenois Canine Coat and Nose Colour HealthGene
- Malinois Canine Coat and Nose Colour HealthGene
- Tervueren Canine Coat and Nose Colour HealthGene
Bernese Mountain Dog von Willebrand’s Disease Type 1 VetGen, Finnzymes, Genetic Technologies
Ltd, Laboklin
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Breed Condition / coat colour Company or testing laboratory
Border Collie Collie Eye Anomaly (CEA) / choroidal
hypoplasia (CH)
Optigen, Genetic Technologies Ltd
Ceroid Lipofuscinosis Optigen, Genetic Technologies Ltd, AHT
Laboklin
Multi drug resistance (MDR1) Laboklin, Finnzymes
Canine Cyclic Neutropenia Laboklin
Canine Coat and Nose Colour HealthGene
Coat Colour Gene Variations VetGen
Coat Length AHT
Trapped Neutrophil Syndrome (TNS) Laboklin, OptiGen
Boston Terrier Early onset, hereditary cataract (HC-HSF4) AHT
Boxer Degenerative Myelopathy University of Missouri
von Willebrand’s Disease Type II Finnzymes
Bobtail gene AHT
Briard Congenital Stationary Night Blindness (CSNB) OptiGen, HealthGene, AHT, Laboklin,
Genetic Technologies Ltd, Genindexe,
Antagene, van Haeringen
Canine Coat and Nose Colour Healthgene
Brittany Canine Coat and Nose Colour HealthGene
Bobtail gene Genoscoper
Bulldog Hyperuricosuria University of CA, AHT
Bullmastiff Dominant Progressive Retinal Atrophy Optigen, Laboklin, Genetic Technologies Ltd
Canine Multi-focal Retinopathy Optigen
Bull Terrier Haemophilia B (Factor IX Deﬁciency) HealthGene, Cornell University
Bull Terrier (Miniature) PLL AHT, OFA
Cairn Terrier Globoid Cell Leukodystrophy HealthGene, Laboklin, Genetic Technologies
Ltd, Genindexe
Pyruvate Kinase Deﬁciency PennGen, Genetic Technologies Ltd,
Laboklin
Haemophilia B HealthGene
Chihuahua (Long and Smooth) Pyruvate Kinase Deﬁciency PennGen, Genetic Technologies Ltd,
Laboklin
Coat length VDA
Chinese Crested Progressive Retinal Atrophy, prcd OptiGen, Genetic Technologies Ltd, Laboklin
PLL AHT, OFA
Collie ( Rough) Collie Eye Anomaly (CEA)/choroidal
hypoplasia (CH)
OptiGen, Genetic Technologies Ltd
Multi drug resistance (MDR1) HealthGene, Genetic Technologies Ltd,
Laboklin, Finnzymes
Progressive Retinal Atrophy, rcd2 Optigen
Canine Cyclic Neutropenia HealthGen, Laboklin, Vetgen
Canine Coat and Nose Colour HealthGene
Collie (Smooth) Collie Eye Anomaly (CEA)/choroidal
hypoplasia (CH)
OptiGen, Genetic Technologies Ltd
Multi drug resistance (MDR1) HealthGene, Genetic Technologies Ltd,
Laboklin, Finnzymes
Progressive Retinal Atrophy, rcd2 Optigen
Canine Cyclic Neutropenia HealthGene, Laboklin, VetGen
Canine Coat and Nose Colour HealthGene
Coton De Tulear Canine Multi-focal Retinopathy OptiGen
von Willebrand’s Disease Type 1 VetGen
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Breed Condition / coat colour Company or testing laboratory
Dachshund (Standard Wire Haired) Narcolepsy OptiGen, HealthGene, Genetic Technologies
Ltd, van Haeringen
Pyruvate Kinase Deﬁciency PennGen, Genetic Technologies Ltd,
Laboklin
Canine Coat and Nose Colour HealthGene
Ceroid Lipofuscinosis University of Missouri
CRD (NPHP4) AHT
Dachshund (Miniature Longhaired) Progressive Retinal Atrophy, cord-1 AHT, Laboklin, University of Missouri,
Genoscoper
Dachshund (Miniature Smooth Haired) Progressive Retinal Atrophy, cord-1 AHT, Laboklin, University of Missouri,
Genoscoper
Coat length AHT
Dachshund (Miniature Wire Haired) Progressive Retinal Atrophy, cord-1 AHT
CRD (NHPH4)
Dalmatian Hyperuricosuria AHT
Canine Coat and Nose Colour HealthGene, VetGen, Laboklin
Deerhound Factor VII Deﬁciency PennGen; VetGen, Laboklin
Coagulation Factor VII deﬁciency AHT
Dobermann Narcolepsy OptiGen, HealthGene, Genetic Technologies
Ltd, van Haeringen, Laboklin
von Willebrand’s Disease Type 1 VetGen, Finnzymes, Laboklin, Genetic
Technologies Ltd
Canine Coat and Nose Colour HealthGene
Dogue de Bordeaux Canine Multi-focal Retinopathy Optigen
English Setter Ceroid Lipofuscinosis University of Missouri
Canine Coat and Nose Colour HealthGene
Entlebucher Mountain Dog Progressive Retinal Atrophy, prcd OptiGen, Laboklin
Finnish Lapphund Progressive Retinal Atrophy, prcd OptiGen, Genetic Technologies Ltd, Laboklin
French Bulldog Hereditary Cataract (HC-HSF4) AHT
Canine Coat and Nose Colour HealthGene
Canine Mask Test HealthGene
German Pinscher von Willebrand’s Disease VetGen, Laboklin
German Longhaired Pointer Canine Coat and Nose Colour HealthGene
German Shepherd Dog Mucopolysaccharidosis VII PennGen, Laboklin
Pyuruvate Kinase Deﬁciency Laboklin
Multi drug resistance (MDR1) Laboklin, Finnzymes
Degenerative Myelopathy University of Missouri
Dwarﬁsm Laboklin
Anal Furunculosis Genoscoper
Canine Coat and Nose Colour HealthGene
Coat length VDA, AHT
German Shorthaired Pointer Cone degeneration Optigen, Genetic Technologies Ltd
von Willebrand’s Disease Type II VetGen, Finnzymes
Canine Coat and Nose Colour HealthGene
German Wirehaired Pointer Haemophilia B Cornell University
von Willebrand’s Disease Type II VetGen, University of Utrecht, Laboklin,
Finnzymes
Canine Coat and Nose Colour HealthGene
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Giant Schnauzer Cobalamin Malabsorption (Methylmalonic
Aciduria)
PennGen
Factor VII deﬁciency VetGen, Laboklin
Glen of Imaal Terrier Progressive Retinal Atrophy, crd-3 Optigen, Bochum University
Gordon Setter Progressive Retinal Atrophy, rcd-4 AHT
Coat Colour Gene Variations VetGen
Great Dane Canine Coat and Nose Colour HealthGene
Canine Mask Test HealthGene
Greyhound Polyneuropathy/Neuropathy (NDRG1) Optigen
Canine Coat and Nose Colour HealthGene
Canine Mask Test HealthGene
Hungarian Kuvasz Progressive Retinal Atrophy, prcd Genetic Technologies, OptiGen
Irish Red & White Setter Canine Leucocyte Adhesion Deﬁciency
(CLAD)
OptiGen, AHT, Genindexe
Progressive Retinal Atrophy, rcd-1 Optigen
von Willebrand’s disease AHT
Irish Setter Canine Leucocyte Adhesion Deﬁciency
(CLAD)
OptiGen, VetGen, HealthGene, AHT,
Laboklin, Genetic Technologies Ltd,
Genindexe, van Haeringen
Progressive Retinal Atrophy, rcd-1 OptiGen, VetGen, HealthGene, AHT,
Laboklin, Genetic Technologies Ltd,
Genindexe, Antagene
Progressive Retinal Atrophy, rcd-4 AHT
Italian Spinone Cerebellar Ataxia AHT
Japanese Chin Canine Coat and Nose Colour HealthGene
Japanese Shiba Inu Coat Length VDA
Keeshond PHPT Cornell University
Kerry Blue Terrier von Willebrand’s Disease Type I VetGen, Finnzymes, Genetic Technologies
Ltd, PennGen
Factor XI Deﬁciency PennGen
Kooikerhondje von Willebrand’s Disease Type II Finnzymes, VetGen, University of Utrecht
Lagotto Romagnolo Juvenile epilepsy Genoscoper
Lancashire Heeler Collie Eye Anomaly (CEA)/choroidal
hypoplasia (CH)
Optigen
PLL AHT, OFA
Large Munsterlander Hyperuricosuria AHT
Canine Coat and Nose Colour HealthGene
Black Hair Follicular Dysplasia HealthGene
Lhasa Apso Renal Dysplasia* VetGen, Genetic Technologies Ltd
Haemophilia B HealthGene, Cornell University
Lowchen Canine Coat and Nose Colour HealthGene
Manchester Terrier von Willebrand’s Disease, Type 1 VetGen, Finnzymes, Laboklin, Genetic
Technologies Ltd
Mastiff Dominant Progressive Retinal Atrophy OptiGen, Laboklin, Genetic Technologies
Ltd, Genindexe, Antagene
Canine Multi-focal Retinopathy Optigen
Miniature Schnauzer Progressive Retinal Atrophy, Type A OptiGen, Genetic Technologies Ltd,
Genindexe
Myotonia congenital HealthGene, PennGen, OptiGen, Laboklin,
Genetic Technologies Ltd
Mucopolysaccharidosis PennGen
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Miniature Pinscher Mucopolysaccharidosis VI PennGen, Genetic Technologies Ltd
Newfoundland Cystinuria OptiGen, HealthGene, PennGen, VetGen, van
Haeringen, VDA, Laboklin, Genetic
Technologies Ltd
Canine Coat and Nose Colour HealthGene
Coat Colour Gene Variations VetGen
Norwegian Elkhound Progressive Retinal Atrophy, prcd Optigen
Old English Sheepdog Multi drug resistance (MDR1) HealthGene, Genetic Technologies Ltd,
Laboklin, Finnzymes
Otterhound Glanzmann’s Thrombasthenia Type 1 Auburn University
Papillion Von Willebrand’s Disease Type 1 VetGen, Finnzymes, Genetic Technologies
Ltd
PRA Genoscoper
Parson Russell Terrier PLL AHT, OFA
Pointer Canine Coat and Nose Colour HealthGene
Coat Colour Gene Variation VetGen
Polish Lowland Sheepdog Bobtail gene Genoscoper
Pomeranian Canine Coat and Nose Colour HealthGene
Poodle (Miniature) Progressive Retinal Atrophy, prcd OptiGen, Genetic Technologies Ltd, Laboklin
von Willebrand’s Disease Type 1 VetGen, Finnzymes, Laboklin, Genetic
Technologies Ltd
Canine Coat and Nose Colour HealthGene, VetGen
Poodle (Standard) Neonatal Encephalopathy University of Missouri, VetGen
von Willebrand’s Disease Type 1 VetGen, Finnzymes, Laboklin, Genetic
Technologies Ltd
Degenerative Myelopathy University of Missouri
Neonatal Encephalopathy with Seizures University of Missouri
Canine Coat and Nose Colour HealthGene, VetGen
Poodle (Toy) Progressive Retinal Atrophy, prcd OptiGen, Genetic Technologies Ltd, Laboklin
von Willebrand’s Disease Type 1 VetGen, Finnzymes, Laboklin, Genetic
Technologies Ltd
Canine Coat and Nose Colour HealthGene, VetGen
Portuguese Water Dog Improper Coat (IC13) Optigen
Progressive Retinal Atrophy, prcd OptiGen, Genetic Technologies Ltd, Laboklin
GM1 gangliosidosis HealthGene, Genetic Technologies Ltd
Canine Coat and Nose Colour HealthGene
Pug Canine Coat and Nose Colour HealthGene
Pyrenean Mountain Dog (Great Pyrenees) Glanzmann’s Thrombasthenia Type 1 Auburn University
Canine Multi-focal Retinopathy OptiGen
Retriever (Chesapeake Bay) Progressive Retinal Atrophy, prcd OptiGen, Laboklin
Degenerative Myelopathy University of Missouri
Exercise Induced Collapse Laboklin
Retriever (Curly Coated) Glycogenosis (GSD) Type IIIa Michigan State
Exercise Induced Collapse Laboklin
Canine Coat and Nose Colour HealthGene
Retriever (Flat Coated) Canine Coat and Nose Colour HealthGene, VetGen, Laboklin
Yellow coat AHT, Finnzymes, Laboklin
Retriever (Golden) Muscular Dystrophy HealthGene, Laboklin
Progressive Retinal Atrophy, prcd Optigen, Laboklin
Progressive Retinal Atrophy (GR_PRA1) AHT
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Retriever (Labrador) Cystinuria PennGen, Genetic Technologies Ltd
Narcolepsy OptiGen, HealthGene, Genetic Technologies
Ltd, van Haeringen, Laboklin
Progressive Retinal Atrophy, prcd OptiGen, Genetic Technologies Ltd, Laboklin
Retinal Dyslasia/OSD Optigen
Haemophilia B HealthGene, Cornell University
Labrador Myopathy (CNM) AHT, Alfort School, Laboklin, VetGen
Exercise Induced Collapse Laboklin
Yellow coat AHT, Laboklin
Canine Coat and Nose Colour HealthGene, VetGen, Laboklin, Genindexe
Coat Colour Gene Variations VetGen, Finnzymes
Retriever (Nova Scotia Duck Tolling) Progressive Retinal Atrophy, prcd OptiGen, Genetic Technologies Ltd, Laboklin
Collie Eye Anomaly (CEA) / choroidal
hypoplasia (CH)
OptiGen, Genetic Technologies Ltd
Rhodesian Ridgeback Degenerative Myelopathy University of Missouri
Rottweiler Coat Length VDA
Russian Black Terrier Hyperuricosuria University of CA, AHT
Samoyed Progressive Retinal Atrophy, X-linked OptiGen, Genetic Technologies Ltd,
Antagene
Retinal Dyslasia/OSD Optigen
Hereditary Nephritis VetGen
Schipperke Mucopolysaccharidosis IIIB PennGen
Coat Colour Gene Variation VetGen
Bobtail gene Genoscoper
Scottish Terrier von Willebrand’s Disease Type III VetGen, Laboklin, Genetic Technologies Ltd
Coat Colour Gene Variation VetGen
Sealyham Terrier PLL AHT, OFA
Shar Pei Canine Coat and Nose Colour HealthGene
Shetland Sheepdog von Willebrand’s Disease Type III VetGen, Laboklin, Genetic Technologies Ltd
Collie Eye Anomaly (CEA)/choroidal
hypoplasia (CH)
Optigen, Genetic Technologies Ltd
Multi drug resistance (MDR1) HealthGene, Genetic Technologies Ltd,
Laboklin, Finnzymes
Canine Coat and Nose Colour HealthGene
Shih Tzu Renal Dysplasia* VetGen, Genetic Technologies Ltd
Siberian Husky Progressive Retinal Atrophy, X-linked OptiGen, Genetic Technologies Ltd,
Anatagene
GM1-gangliosidosis Laboklin
Silky Terrier Progressive Retinal Atrophy, prcd Optigen
Sloughi Progressive Retinal Atrophy, rcd-1a OptiGen, HealthGene, AHT, Laboklin,
Genindexe, Antagene, Genetic Technologies
Ltd
Soft Coated Wheaten Terrier Renal Dysplasia* VetGen, Genetic Technologies Ltd
Spaniel (American Cocker) Progressive Retinal Atrophy, prcd OptiGen, Genindexe, Genetic Technologies
Ltd, Laboklin
Phosphofructokinase (PFK) Deﬁciency OptiGen, Health Gene, VetGen, PennGen,
AHT, Genetic Technologies Ltd,
Genindexe, Laboklin
Coat Colour Variations VetGen
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Spaniel (Clumber) Pyruvate Dehydrogenase Phosphatase
Deﬁciency (PDP 1)
Genetic Technologies Ltd, University of
Missouri, AHT, Laboklin; Genoscoper
Spaniel (Cocker) Progressive Retinal Atrophy, prcd OptiGen, Genetic Technologies Ltd, Laboklin
Phosphofructokinase (PFK) Deﬁciency OptiGen, VDA, HealthGene, van Haeringen,
Genindexe
Familial Nephropathy Optigen, Genetic Technologies Ltd, Anatgene
Canine Coat and Nose Colour HealthGene
Spaniel (English Springer) Fucosidosis AHT, PennGen, Finnzymes, Laboklin,
Genetic Technologies Ltd, Genindexe,
Finnzymes
Phosphofructokinase (PFK) Deﬁciency OptiGen, VetGen, HealthGene, AHT,
PennGen, VDA, Laboklin, Genetic
Technologies Ltd, Genindexe, van
Haeringen, University of Missouri
PRA – cord1 AHT, Finnzymes, Laboklin, University of
Missouri, Genoscoper
Canine Coat and Nose Colour HealthGene
Spaniel (Field) Canine Coat and Nose Colour HealthGene
Spaniel (Sussex) Pyruvate Dehydrogenase Phosphatase
Deﬁciency (PDP 1)
AHT, Genetic Technologies Ltd, University
of Missouri, Laboklin, Genoscoper
Spanish Water Dog Progressive Retinal Atrophy, prcd OptiGen, Genetic Technologies Ltd
Bobtail gene Genoscoper
Staffordshire Bull Terrier Hydroxyglutaric acidurea, L-2-HGA AHT, University of Missouri, Laboklin
Hereditary cataract , HC-1 AHT
Canine Coat and Nose Colour HealthGene
Swedish Lapphund Progressive Retinal Atrophy, prcd OptiGen, Genetic Technologies Ltd, Laboklin
Swedish Vallhund Bobtail gene Genoscoper
Tibetan Terrier PLL AHT, OFA, University of Missouri
NCL OFA
Weimaraner Coat Length AHT, VDA
Welsh Corgi (Cardigan) Progressive Retinal Atrophy, rcd-3 OptiGen, HealthGene, Laboklin, Genetic
Technologies Ltd, Genindexe, Anatagene,
VetGen, University of Michigan
X-linked severe combined immunodeﬁciency
(SCID)
PennGen, Laboklin, Genetic Technologies
Ltd
Degenerative Myelopathy University of Missouri
Canine Coat and Nose Colour HealthGene
Coat Length VDA
Welsh Corgi (Pembroke) von Willebrand’s Disease TypeI VetGen, Finnzymes, Genetic Technologies
Ltd, Laboklin
Severe combined immunodeﬁciency (SCID) PennGen, Genetic Technologies Ltd
Degenerative Myelopathy University of Missouri
Coat length AHT, VDA
Bobtail gene AHT
West Highland White Terrier Pyruvate Kinase (PK) Deﬁciency HealthGene, PennGen, VDA, Laboklin,
Genetic Technologies Ltd, Genindexe,
VetGen
Globoid Cell Leukodystrophy HealthGene, Laboklin, Genetic Technologies
Ltd, Genindexe
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1,000 genomes project revealed that humans carry, on
average, between 250 and 300 recessive mutations and at
least 50 mutations previously associated with inherited
disorders, and it seems reasonable to assume the average
dog will carry the same burden of disease-associated
variants (Durbin et al. 2010). Expecting breeding dogs to
be clear of all risk alleles, therefore, is unrealistic and will
severely jeopardise breed diversity.
Recessive mutations for late-onset conditions are noto-
riously difﬁcult to eliminate if a DNA test is not available,
and, in the absence of effective selective pressure, can
become common within a breed. Nevertheless, robust data
regarding mutation frequency are often unavailable, pos-
sibly because the data are rarely required for publication,
and as the number of DNA tests available increases, it will
become increasingly important for veterinarians and
breeders to be able to sensibly prioritise tests for speciﬁc
breeds. DNA test providers should be prepared to provide
accurate information regarding the frequency of a speciﬁc
mutation in relevant breeds, both when a DNA test is ini-
tially made available and at regular intervals, so progress
toward the genetic improvement of the breed can be
monitored. Obtaining such estimates might require sam-
pling of additional individual dogs from a cross section of
the gene pool because DNA samples collected during a
genetic investigation are usually biased toward affected
individuals and closely related dogs.
Numerous DNA tests are available for autosomal
recessive mutations, far too many to describe individually,
so this review summarises two representative examples,
along with background behind their identiﬁcation. Both
mutations have been reported in the scientiﬁc literature and
both are relevant to a large number of breeds. The muta-
tions are those for progressive rod cone degeneration (prcd)
(Zangerl et al. 2006) and primary lens luxation (PLL)
(Farias et al. 2010).
Progressive rod cone degeneration (prcd) is a late-onset
form of progressive retinal atrophy (PRA) that affects
multiple breeds. Prior to characterization of this disease at
the molecular level, elegant interbreed crosses were
undertaken to determine that the phenotypically similar
diseases that were segregating in multiple breeds, includ-
ing the miniature poodle, the English and American
cocker spaniels, the Labrador retriever, the Australian
cattle dog, the Nova Scotia duck tolling retriever, and the
Portuguese water dog, were in fact allelic (Aguirre and
Acland 1988, 2006). However, when prcd-affected dogs
were mated to PRA-affected dogs of the Border Collie,
Basenji, and Italian greyhound breeds, the progeny were
normal, indicating that these breeds are affected by
genetically distinct forms of disease. The prcd locus was
mapped to a large region on CFA9 in 1998 (Acland et al.
1998), before the canine genome sequence was available
and while tools with which to investigate the canine
genome were relatively unsophisticated compared to those
available today. The whole-genome radiation panels that
were available at the time, and that would have been
useful to investigate any other region of the genome, did
not signiﬁcantly help to locate the mutation because they
were both TK1 selected (Priat et al. 1998), and since TK1
was tightly linked to the prcd locus, it was difﬁcult to
order positional candidate genes within the prcd critical
region. However, the fact that a genetically identical dis-
ease segregated in so many breeds proved to be invaluable
as it allowed the use of linkage equilibrium mapping
across affected breeds to considerably narrow the prcd-
associated region (Goldstein et al. 2006) and led to the
eventual identiﬁcation of a single nucleotide substitution
in the second codon of a previously unknown gene that is
now known to be the cause of prcd in over 30 different
breeds (Zangerl et al. 2006). A DNA test for the prcd
mutation is provided by OptiGen (www.optigen.com), a
service company cofounded by ophthalmologists Gregory
Acland and Gustavo Aguirre to provide DNA-based
diagnoses and information about inherited diseases of
dogs. The company provides breeding advice as well as
comprehensive, breed-speciﬁc information for owners
Table 1 continued
Breed Condition / coat colour Company or testing laboratory
Whippet Collie Eye Anomaly (CEA)/choroidal
hypoplasia (CH) – Longhaired Whippets only
Optigen
Canine Multidrug Sensitivity Test (MDRI) HeathGene
Canine Coat and Nose Colour HealthGene
Canine Mask Test HealthGene
Yorkshire Terrier Progressive Retinal Atrophy, prcd Optigen
a Linked marker test, not a mutation-based, gene test
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speciﬁc breeds and whether genetically distinct forms of
PRA are known to exist in the same breed.
The mutation for PLL is another example of a mutation
that segregates in multiple breeds, all of which can take
advantage of a DNA test. PLL is an inherited deﬁciency of
the lens suspensory apparatus, the zonule, which is a sys-
tem of ﬁbres that suspend the lens from the ciliary body,
maintaining it on the visual axis and in contact with the
anterior surface of the vitreous body. In dogs affected with
PLL, ultrastructural abnormalities of the zonular ﬁbres are
already evident at 20 months of age (Curtis 1983), long
before the lens luxation that typically occurs when the dogs
are 3–8 years old, as a result of degeneration and break-
down of the zonules that cause the lens to be displaced
from its normal position within the eye (Curtis 1990; Curtis
and Barnett 1980; Curtis et al. 1983; Morris and Dubielzig
2005). In the majority of cases the dislocated lens will pass
into the anterior chamber where its presence is likely to
cause acute glaucoma. The condition has been recognized
as a canine familial disorder for more than 100 years (Gray
1909, 1932) and is encountered at high frequency in several
terrier breeds and in some other breeds with probable ter-
rier coancestry (Curtis 1990; Curtis and Barnett 1980;
Curtis et al. 1983; Morris and Dubielzig 2005; Willis et al.
1979). In 2010 a mutation in ADAMTS17 was described as
the cause of PLL in three breeds, the Miniature Bull terrier,
the Lancashire Heeler, and the Jack Russell terrier. The
mutation is a G?A substitution at c.1473?1, which
destroys a splice donor recognition site in intron 10 and
causes exon skipping that results in a frameshift and the
introduction of a premature termination codon (Farias et al.
2010). A subsequent publication, targeted at a veterinarian
audience, reports 14 additional breeds in which the iden-
tical mutation segregates, and documents the frequency of
the mutation in a subset of breeds (Gould et al. 2011). The
great majority of PLL-affected dogs are homozygous for
the mutation, but a small minority are heterozygous,
leading to speculation that carriers, of some breeds at least,
might be at increased risk of developing the condition
compared to dogs that are homozygous for the wild-type
allele (Farias et al. 2010). A DNA test for the ADAMTS17
substitution is available via each of the two research groups
that collaborated to identify the mutation, the Animal
Health Trust (www.aht.org.uk) and the University of
Missouri, via The Orthopaedic Foundation for Animals
(http://www.offa.org/dnatesting/pll.html), as well as a
number of other DNA-testing providers that have used the
published data to develop their own tests. Both the Animal
Health Trust and The Orthopaedic Foundation for Animals
provide extensive information regarding the clinical aspects
of PLL, the risk to dogs with each of the three possible
genotypes of developing PLL, and also breeding advice for
owners.Themutationisfrequentinseveralbreeds,soadvice
is provided that counsels breeders to include heterozygotes
inthebreedingpopulationtoavoidpushingbreedsthrougha
genetic bottleneck. Both prcd and PLL are examples of
where rigorous scientiﬁc investigations have provided the
data for DNA tests that are provided in a suitable context for
dog owners and breeders to use to full advantage.
Validating which breeds a speciﬁc DNA test should be
usefully offered to is an important consideration for the
DNA test provider, and many DNA test providers,
including the Animal Health Trust and OptiGen
(N. Holmes and S. Pearce-Kelling, personal communica-
tions), have a policy of restricting all tests to only those
breeds in which the mutation has previously been identiﬁed
and is also associated with disease. The risk associated with
speciﬁc mutations might vary, depending on the genetic
background, so simply establishing that a mutation is
segregating within a breed does not necessarily justify
making the test available to that breed.
Both prcd and PLL are genetically ‘‘simple’’ conditions,
that is, the mutations are completely penetrant and homo-
zygous dogs invariably develop the associated condition
during their lives. Examples are emerging of recessive
conditions for which the associated mutation is not com-
pletely penetrant, indicating that other factors, either
genetic or environmental, play a role in the development of
the disease. Researchers need to provide dog breeders with
speciﬁc counselling for such conditions to ensure that they
appreciate that not all dogs that are homozygous for dis-
ease-associated variants will develop clinical signs during
their lives, but that they will pass these mutations onto their
offspring (who may inherit different modiﬁer alleles and be
affected).
One example of a disease that segregated as a Mende-
lian trait within an inbred research colony but appeared
genetically more complex in the general pet population is a
form of retinal degeneration described in the miniature
long-haired dachshund (MLHD). The disease was origi-
nally described as an early-onset, autosomal recessive
PRA, with all affected dogs within an inbred research
colony displaying ophthalmologic abnormalities that were
detectable by electroretinogram (ERG) by 6 weeks of age
and by fundoscopy at 25 weeks of age. The dogs were
invariably blind by the time they were 2 years of
age (Curtis and Barnett 1993). A subsequent ERG study
identiﬁed an initial reduction of the cone photoreceptor
function which led to the condition being reclassiﬁed as a
cone–rod dystrophy (CRD) rather than a rod-led PRA, and
the disease was termed cord1 for cone–rod degeneration 1
(Turney et al. 2007). The same condition has also been
referred to by others as crd4 for cone–rod degeneration 4
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cord1 was mapped to a large region on CFA15, and a
mutation in RPGRIP1 was identiﬁed that cosegregated
completely with cord1 in the research colony (Mellersh
et al. 2006a). The mutation is a 44-bp insertion of an A29
tract ﬂanked by a 15-bp duplication in exon 2 of the gene,
which creates a frameshift and introduces a premature stop
codon early in exon 3. Mutations in RPGRIP1 have been
associated with Leber congenital amaurosis (LCA) (Dryja
et al. 2001), retinitis pigmentosa (RP) (Booij et al. 2005),
and CRD (Hameed et al. 2003) in humans, as well as
inherited retinal abnormalities in mice (Zhao et al. 2003),
which suggests that it plays an important role in visual
function. Within the research colony of MLHDs there was
complete correlation between the RPGRIP1 genotype and
phenotype of the dogs with respect to their cord1 pheno-
type, whereas in the pet MLHD population this was not
the case (Miyadera et al. 2009). Outside of the colony
there was considerable variation in the age of onset of
retinal degeneration in dogs that were homozygous for the
RPGRIP1 insertion (RPGRIP1
-/-), which has also been
identiﬁed in other breeds, including the English Springer
Spaniel (ESS) and the Beagle. However, all RPGRIP1
-/-
Beagles and MLHDs showed reduced or absent ERG cone
responses, even in the absence of ophthalmoscopic
abnormalities, a ﬁnding that has also been corroborated by
Busse et al. (2011). Together, these ﬁndings suggest that
additional mutations which modify the age of onset of
ophthalmoscopic abnormalities associated with the
RPGRIP1 mutation are involved. Because the original
research colony used was developed from a very small
number of dogs, it is likely that the colony was ﬁxed for
these additional loci which, therefore, went undetected
until the more outbred pet population was investigated. A
recent association study using RPGRIP1
-/- MLHDs that
had either early- or late-onset cord1 has indeed revealed
a second locus that segregates with early-onset disease
(K. Miyadera, Cambridge, 2010, personal communication),
indicating that early-onset CRD in MLHDs is more likely
to be a digenic condition and that the RPGRIP1 insertion
alone causes a late-onset CRD, although ERG abnormal-
ities may be detected early in life. The RPGRIP1 insertion
is very frequent within both MLHD and ESS populations,
probably due to the lack of effective selection against the
late-onset CRD with which it is associated. Breeders
should thus be mindful to breed with carriers so that the
genetic diversity of their breed(s) is not unduly compro-
mised and to consider the RPGRIP1 genotype of their
dogs alongside all the other factors they use to weigh a
dog’s breeding potential.
Two additional examples of recessive mutations that are
not completely penetrant but are highly associated with
disease (and therefore sound candidates for a DNA test) are
those for degenerative myelopathy (DM) in the Boxer,
Cardigan Welsh Corgi, Chesapeake Bay Retriever, German
Shepherd, Kerry Blue Terrier, Pembroke Welsh Corgi,
Rhodesian Ridgeback, and Standard Poodle and
hyperuricosuria.
DM is a severe, incurable disease of the spinal cord
where demyelination and axonal loss contribute to degen-
eration of the white matter of the spinal cord resulting in
progressive paralysis. The disease has an insidious onset,
typically between 8 and 14 years of age, so affected dogs
may well have been bred well before their clinical signs
develop. The mutation that is tested for, a single-nucleotide
missense mutation in SOD1, greatly increases an individual
dog’s risk of developing DM, although a minority of dogs
that carry two copies of the mutation remain free of clinical
signs associated with the condition during their lifetime. It
is suspected that there are additional mutations and/or
environmental factors that modify the effects of the DM
mutation and explain why some dogs remain healthy
(Awano et al. 2009). The orthopaedic foundation for ani-
mals (OFA) makes it very clear on their DNA-testing
website that the DM carrier status of dogs should be con-
sidered alongside other factors, such as breed type and
temperament, and that breeders should not ‘‘over-empha-
size DNA test results’’ (http://www.offa.org/dnatesting/
dmbreederguide.html).
Another example of a disease-associated risk factor that
is incompletely penetrant and for which there is a com-
mercially available DNA test is the mutation associated
with hyperuricosuria, or elevated levels of uric acid in the
urine. This trait predisposes dogs to form stones in their
bladders, or sometimes kidneys, which often have to be
removed surgically and can be difﬁcult to treat. The
associated variant, a missense mutation in SLC2A9, is
associated with hyperuricosuria in several different breeds,
including the Dalmatian (a breed that is ﬁxed for the
mutation), but as with DM, not all dogs that are homozy-
gous for the mutation develop urate stones, indicating that
other factors are involved (Bannasch et al. 2008; Karmi
et al. 2010). The DNA tests for these and other disease-
associated variants provide dog breeders with invaluable
tools with which to reduce the frequency of inherited dis-
eases from breeds at risk, and, provided the mutation being
tested for is highly associated with the disease in question,
it is difﬁcult to justify not making such DNA tests available
to the public. Provided full information is available to
enable the nonscientist to understand the level of risk
involved, that the mutation is not fully penetrant and that
other factors might contribute to the development of dis-
ease, then breeds will certainly beneﬁt in the long term
from the availability of such tests.
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Dominant mutations obviously present dog breeders with a
different dilemma from recessive mutations; because all
offspring that inherit a disease-associated dominant muta-
tion will develop clinical signs at some stage during their
lives, it is harder to justify breeding with animals that carry
dominant mutations. Depending on the frequency of the
mutation within a population, tests for dominant mutations
have the potential to result in more dogs being prevented
from breeding, and consequently do more damage to the
genetic diversity of a breed, than DNA tests for recessive
mutations. As a result, researchers have an even greater
responsibility to limit the availability of DNA tests for
dominant mutations to those that are highly associated with
disease. They need to exercise sensible restraint for
mutations that have incomplete penetrance (particularly if
the level of penetrance is very low), especially if the dis-
ease-associated mutation is frequent within a breed. There
are several DNA tests currently available that are based on
dominant or codominant mutations, including the RHO
mutation for an autosomal dominant form of PRA in the
English Mastiff offered by OptiGen (www.optigen.com)
(Kijas et al. 2002), the mutation in HSF4 that is associated
with hereditary cataract in the Australian Shepherd that is
offered by the Animal Health Trust (www.AHT.org.uk)
(Mellersh et al. 2006b, 2009), and the polymorphisms
associated with renal dysplasia in multiple breeds that is
offered by DoGenes (www.dogenes.com) (Whiteley et al.
2011).
Complex conditions
Genetically complex conditions that result from mutations
in multiple genes or the interaction between genes and the
environment represent a vastly different scenario from
genetically simple traits. Individual polymorphisms will
invariably be identiﬁed that increase an individual dog’s
risk of developing an associated condition but cannot
predict with absolute certainty whether the dog will
become clinically affected. Since the canine genome
sequence became available, four different, increasingly
dense, whole-genome SNP arrays have been developed
[the 27 K(v1) and 50 K(v2) canine Affymetrix SNP chips
and the Illumina CanineSNP20 and CanineHD Bead-
Chips], providing increasingly sensitive means with which
to identify regions of the genome associated with complex
traits of interest. Several reports have been published that
identify regions of the canine genome associated with
complex traits (Bannasch et al. 2010; Wilbe et al. 2010),
and precise variants underlying these associations will
almost certainly be identiﬁed in the near future.
Associations between speciﬁc genes and complex condi-
tions are obviously important and will make profound
contributions toward our understanding of gene function
and disease aetiology, but they present the scientist with a
dilemma when it comes to deciding whether to make a
DNA test available based on risk factors. There is a need
for dog owners and breeders to balance the desire to breed
for ‘‘genetic health’’ by eliminating disease-associated
mutations from their breed with the need to maintain
genetic diversity. As stated already, most dog breeders are
not generally in a position to objectively evaluate the
speciﬁc level of risk associated with a given mutation
from a scientiﬁc publication. There will be a tendency for
all mutations described as ‘‘risk factors’’ to be considered
similarly, regardless of the level of risk they convey, and
once a DNA test becomes commercially available, many
breeders will have their dogs tested and avoid breeding
with dogs that carry that mutation. It is, therefore, irre-
sponsible of DNA test providers to offer tests for isolated
mutations that are only weakly associated with disease;
these mutations are likely to be minor modiﬁers of more
major risk factors and eliminating them may reduce
genetic diversity without dramatically reducing the prev-
alence of disease. Increasingly, research to identify canine
disease-associated mutations is being funded by dog-ori-
ented organisations, and researchers need to resist pres-
sure to make DNA tests available prematurely to
compensate these stakeholders for their ﬁnancial and
moral support.
Summary
Genetic tools available with which to dissect the canine
genome are becoming increasingly sophisticated, and the
number of disease-associated genetic variants that will be
identiﬁed over the next few years will undoubtedly
increase dramatically. These mutations will form the basis
of extremely valuable tools that dog owners and breeders
will clamour to use to eliminate both Mendelian and
complex inherited conditions from their beloved breeds. If
the public is to maintain conﬁdence in these new tools,
scientists must be responsible custodians of their ﬁndings,
and make DNA tests commercially available only if they
can be accompanied by straightforward, transparent, user-
friendly advice on how they should be used to reduce the
frequency of disease without reducing genetic diversity
unnecessarily.
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